SILVER SPRING
Ocrevus cleared for pediatric multiple sclerosis
- Sponsor
- Genentech $RHHBY
- Drug
- Ocrevus · ocrelizumab
- Indication
- relapsing-remitting multiple sclerosis
FDA approved Ocrevus (ocrelizumab) IV infusion for relapsing-remitting multiple sclerosis in pediatric patients aged 10 and older.
What this means
Ocrevus is an intravenous antibody treatment that targets B cells, a type of immune cell involved in multiple sclerosis. The FDA has now approved its use for children aged 10 and older with relapsing-remitting MS, expanding its previous adult-only label. This decision gives younger patients access to a treatment that could help manage their condition and reduce relapses.
Drug Watch — recent news on Ocrevus
- Thank you! Ocrevus and Kesimpta will remain on the PBS - MS Australia
- Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved? - The Guardian
- MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS - MS Australia
- Win for MS patients facing drug pricing cliff - ABC News & Headlines – Australian Broadcasting Corporation
- Teva, Polpharma ink licensing pact for biosimilar targeting Roche’s Ocrevus - MSN
Sponsor Watch — recent news on Genentech
- Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
- Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate
- Slate Medicines Appoints Mark W. Hahn to Board of Directors
- Roche Holding (SWX:ROP) Could Be 7% Undervalued On Pipeline Momentum
- Roche (SWX:ROG) Stock Could Trade At A Discount Despite Its 35% Run